_id
691053abccc777a4e85d5535
Ticker
CPIX
Name
Cumberland Pharmaceuticals Inc
Exchange
NASDAQ
Address
1600 West End Avenue, Nashville, TN, United States, 37203
Country
USA
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Currency
USD
Website
https://www.cumberlandpharma.com
Description
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Last Close
2.49
Volume
37827
Current Price
2.53
Change
1.6064257028112285
Last Updated
2025-11-29T11:47:29.161Z
Image
data:image/webp;base64,UklGRgYIAABXRUJQVlA4WAoAAAAQAAAAOAAAPwAAQUxQSB8EAAABoHVtkyHZlv9FRG3bNo5t27atK9u2bds27mzbtjW7IjO+i1ZNTURMAKpXLDMJgp5oOHyunmEY+tbkHiBmgos4smZihUIw7ib+M6ZOYgYAQ1a55DfyvxqJARi02nGPf0eG10hM0G/9G79nkNlz1EcVow77mMFcpkyyNmIYeMTPjOw52LQuqljvY4YntlkTRb9LGJ7Zdj0Mk56nJ3ZYC8M8n7EMtozIOaXk+e/x6FWYSnWKWV+wJMnI7p7YPPjfGAgAiJlUIhj+Bp2R3YON/tvX7zzz2N23XHPvJScfsdeGCwwXAGLSmeIWluGZZPrs0XP2XH3B8X0BQLFQYpDx07MXbDYGEJMODNuz9CC/vH6XefuhtWgvLDrH53gOkvzjwe2GQEzawtCP6fz9mjUGAIAWZioCAIqFE4OMnDwx+M3JE6Da1gGM304cB4EWKmi3VdPsKfjHSUNh0qrXG7xzEsQMHXdAMnvml5tCtcWKPAJiigo7I7MHr+oPa3beOSgUlVZBJudLU2BNLukLQVULdaXS3VPKEc0YJT+fB9awKBSVLZIZbB7JPQVJOj+fAQUgqFww/tQzz7/8hnuffv2bfzJJRvIUdL4yGAJode1qv/FLbHroza//zWD2XPIaKNBLukGKoihMBc1t4kbnvZMYXnIzGHaGVddaRNQKEwDFkuf9QOfb/SE3LAjrttZiBsHwQ34kd4ft/+4QFFKTRjPBmJv5DDDd35kPalIbQExwOBcG7uWfxw2BSKFSE0ALXHAUsCad354wCwC0MJU6QDDyIAjuZVfw/6f3XbAPmooVRWGN1UEwsbdi7t/pHmT+6I5D1p13IOopAhh2o0e4B0l2ff/6g1eddvAeW2+09uqr9O4GKADDWSyDjOSe2GbwvzGQyqQBgqtZZjZG5JS89JRy4j/dILJC7waRC+mpoe3gf9UZljoFjaLYt2SZ6yIFBr29cxPAsOy7zGXUQQrFzDf+HtsChv7H/8PsKbpHCwX6HfALb4S2gCqmX/43mT1FNaJWCARj9/uYKa8AawVRwZRjP2IwUukpZ/47FqZmVhSmaJRJ29/xO6OLt0HRtirQZ5Xz3uhikAz+NwaCljZ2iZ0uevFfMtz5y8xOADEBihmbnXDbc5//9NevK8xadOmVN9h+7xOveuK9X4Mkk+dw7gRD52ImaLThw9dODLaZ3VOQUfJMGCoWKxRQLNwQ2Uv3lHOwMUpeA5WqmophEWew0+S8VFTQvYqFU0fhzIdABXULT/x0VZigXpE9s+ucITB0f1uRPZFzbpsPqqhPZPdg8Pvz54OYoDbZM4P5ixs3HwKoop6KhXMk8vOb916iPwBT1FWxsEd+YI1+AGAmqK9iofhtIwisUNRbsVBeH71MUHvFCreiQE9ULLcJrEcIJo+D9IjuBwBWUDggwAMAADASAJ0BKjkAQAA+tUadSicjoqGx852w4BaJZgDGb+zKimGhZ7bbngNMl3j2uzvznSIrt7NkzVUE8A82PoDZwPpz2B/1j6rnoUfrSUXGCGD+wPV8Kd3Awv2v5I6Ide7hswLoEUruMl3m9/QaF82ojhAlEXJvgOc30hVlwZNLf7H31N4I17B2dVazYEpi8HoBmTv69DvRVksUQQAA/vypC5v5iDyxW5/4oDATTt9bY3PtA6FLrZz7R7ICyUZuHOuvVgu7DblJNrNkY7QCW4fphf8Y8/tBP9Nfm7Erlf9YEWwqluDrpeHJUPPWeI74l1liXsjGgEvYakL4bK5HFTJPYpAovs/ndKJ6kiKdtDSM8FNh5v88Okt7NEf9ccppLBSrjyMnZDDRslnn6acsndHvrz6H3u657yDahR9WIQ33JGavT6z9v57f0p1xcttMVBRfk2wTqf8rM5XNCsgl2nk9kDClJ4nw/VKfC9uqSWGHbG9v9THvHPPAPvR5tQVjn26uzpC61mpIxLDpwB5mU3vyAtKl23RA1ogyvEbS7WzHji/vLRhCKafPIFc0LVtAP6teOhSl4vYbWfv4/5gMYK5Z8qrY02sKwSzmaqJUK9LAk4gIVfvNN25w6MmB0VTbIbp7KuAlFCCs/ETeyQ3R+96coyOuonA8LZ/4Ket1GBOdeb3G6ALi64GB1MUa6uxV8G8NgyB+ik75hVxurCqNU1QYtaLhdslJgs7+Ln/9ARcM/EtSUYgfV0pebv+BoVJYl9nFbBiZEjIzRzV6/KcSGKbOOSpD6eu/K2S+Sqsrf+kwVJcfqbO48dAHHZh7xyHeMIPptDF4ur31lhlGIZAR2kzC0pDglB8XTl/5vNqdydxFqTfd1TQqpcWUwocoERQRQtCir4n03hwEX/wv4+Wj4rhgUaAOcDZC/EnHWEjqO5diWAcFTbi9AH+tavnyMehLI2ebhtXRINib/QlR+qUSRBye/aLwdVkd4+JO2Ev+ktLCuEhwLdF0yjx+X0DHXHgNkGPn31SS7NEo74M5EZSGNdA034SfHzRcWwy/MVox8H9PPQ1UJt49NJJ4QMmgcN/yWgKDld6kM4B5fvF+NWJm2TziGYbeSYG0cGeTNQKcqFBgfvJHSYafrKPC3tpMYAIVpNjh9+i1nvGgORqL6TzaBxwwH0a9Z6uiGqm9/w58mw/ubRc46aJVV59FPn71X8Y2XVGEj9fVRsBC2XDNQX6RZz/x1dbhP6tMDe7rHo+trDP72kn0mKOkmSXm4hZU6sgt+9gAAA==
Ipo Date
2009-08-11T00:00:00.000Z
Market Cap
33809456
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.99
Sentiment Sources
2
Rating
5
Target Price
8.5
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
8292362
Cost Of Revenue
988760
Gross Profit
7303602
Operating Expenses
9268862
Operating Income
-1965260
Interest Expense
109699
Pretax Income
-1943376
Net Income
-1940764
Eps
-0.12978275162726302
Dividends Per Share
-
Shares Outstanding
14956627
Income Tax Expense
5670
EBITDA
-795873
Operating Margin
-23.69964070550707
Total Other Income Expense Net
21884
Cash
15196745
Short Term Investments
-
Receivables
10430602
Inventories
2934723
Total Current Assets
29939448
Property Plant Equipment
7863827
Total Assets
65898560
Payables
13832497
Short Term Debt
401445
Long Term Debt
5240733
Total Liabilities
40097856
Equity
26119854
Depreciation
1037804
Change In Working Capital
808423
Cash From Operations
187180
Capital Expenditures
23790
Cash From Investing
-690837
Cash From Financing
-386879
Net Change In Cash
-890536
PE
-
PB
1.4312813540228824
ROE
-7.430225299115378
ROA
-2.945078010809341
FCF
163390
Fcf Percent
0.01970367429690117
Piotroski FScore
2
Health Score
26
Deep Value Investing Score
5.5
Defensive Investing Score
5.5
Dividend Investing Score
3
Economic Moat Investing Score
5.3
Garp Investing Score
3
Growth Investing Score
2.5
Momentum Investing Score
4.5
Net Net Investing Score
3
Quality Investing Score
3.5
Value Investing Score
4
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
8292362
Quarters > 0 > income Statement > cost Of Revenue
988760
Quarters > 0 > income Statement > gross Profit
7303602
Quarters > 0 > income Statement > operating Expenses
9268862
Quarters > 0 > income Statement > operating Income
-1965260
Quarters > 0 > income Statement > interest Expense
109699
Quarters > 0 > income Statement > pretax Income
-1943376
Quarters > 0 > income Statement > net Income
-1940764
Quarters > 0 > income Statement > eps
-0.12978275162726302
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
14953944
Quarters > 0 > income Statement > income Tax Expense
5670
Quarters > 0 > income Statement > EBITDA
-795873
Quarters > 0 > income Statement > operating Margin
-23.69964070550707
Quarters > 0 > income Statement > total Other Income Expense Net
21884
Quarters > 0 > balance Sheet > cash
15196745
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
10430602
Quarters > 0 > balance Sheet > inventories
2934723
Quarters > 0 > balance Sheet > total Current Assets
29939448
Quarters > 0 > balance Sheet > property Plant Equipment
7863827
Quarters > 0 > balance Sheet > total Assets
65898560
Quarters > 0 > balance Sheet > payables
13832497
Quarters > 0 > balance Sheet > short Term Debt
401445
Quarters > 0 > balance Sheet > long Term Debt
5240733
Quarters > 0 > balance Sheet > total Liabilities
40097856
Quarters > 0 > balance Sheet > equity
26119854
Quarters > 0 > cash Flow > net Income
-1940764
Quarters > 0 > cash Flow > depreciation
1037804
Quarters > 0 > cash Flow > change In Working Capital
808423
Quarters > 0 > cash Flow > cash From Operations
187180
Quarters > 0 > cash Flow > capital Expenditures
23790
Quarters > 0 > cash Flow > cash From Investing
-690837
Quarters > 0 > cash Flow > cash From Financing
-386879
Quarters > 0 > cash Flow > net Change In Cash
-890536
Quarters > 0 > ratios > PE
-0.12978275162726302
Quarters > 0 > ratios > PB
1.4312813540228824
Quarters > 0 > ratios > ROE
-7.430225299115378
Quarters > 0 > ratios > ROA
-2.945078010809341
Quarters > 0 > ratios > FCF
163390
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
0.01970367429690117
Quarters > 0 > health Score
26
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
10837363
Quarters > 1 > income Statement > cost Of Revenue
2011389
Quarters > 1 > income Statement > gross Profit
8825974
Quarters > 1 > income Statement > operating Expenses
9573452
Quarters > 1 > income Statement > operating Income
-747478
Quarters > 1 > income Statement > interest Expense
109547
Quarters > 1 > income Statement > pretax Income
-729536
Quarters > 1 > income Statement > net Income
-740740
Quarters > 1 > income Statement > eps
-0.04951273331623954
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
14960596
Quarters > 1 > income Statement > income Tax Expense
5671
Quarters > 1 > income Statement > EBITDA
699114
Quarters > 1 > income Statement > operating Margin
-6.897231365231561
Quarters > 1 > income Statement > total Other Income Expense Net
17942
Quarters > 1 > balance Sheet > cash
16087281
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
10316911
Quarters > 1 > balance Sheet > inventories
3222872
Quarters > 1 > balance Sheet > total Current Assets
31205329
Quarters > 1 > balance Sheet > property Plant Equipment
7423201
Quarters > 1 > balance Sheet > total Assets
67907149
Quarters > 1 > balance Sheet > payables
13446531
Quarters > 1 > balance Sheet > short Term Debt
386077
Quarters > 1 > balance Sheet > long Term Debt
5240733
Quarters > 1 > balance Sheet > total Liabilities
40228222
Quarters > 1 > balance Sheet > equity
27989795
Quarters > 1 > cash Flow > net Income
-740740
Quarters > 1 > cash Flow > depreciation
1319103
Quarters > 1 > cash Flow > change In Working Capital
1675827
Quarters > 1 > cash Flow > cash From Operations
843801
Quarters > 1 > cash Flow > capital Expenditures
26486
Quarters > 1 > cash Flow > cash From Investing
285864
Quarters > 1 > cash Flow > cash From Financing
-150797
Quarters > 1 > cash Flow > net Change In Cash
978868
Quarters > 1 > ratios > PE
-0.04951273331623954
Quarters > 1 > ratios > PB
1.3362545170480884
Quarters > 1 > ratios > ROE
-2.6464645418088986
Quarters > 1 > ratios > ROA
-1.0908129864206197
Quarters > 1 > ratios > FCF
817315
Quarters > 1 > ratios > Piotroski FScore
2
Quarters > 1 > ratios > fcf Percent
0.07541640895483523
Quarters > 1 > health Score
31
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
11713055
Quarters > 2 > income Statement > cost Of Revenue
1425714
Quarters > 2 > income Statement > gross Profit
10287341
Quarters > 2 > income Statement > operating Expenses
8995394
Quarters > 2 > income Statement > operating Income
1291947
Quarters > 2 > income Statement > interest Expense
163802
Quarters > 2 > income Statement > pretax Income
1253854
Quarters > 2 > income Statement > net Income
1257068
Quarters > 2 > income Statement > eps
0.08237762113114803
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
15259824
Quarters > 2 > income Statement > income Tax Expense
5670
Quarters > 2 > income Statement > EBITDA
2734424
Quarters > 2 > income Statement > operating Margin
11.02997467355869
Quarters > 2 > income Statement > total Other Income Expense Net
-38093
Quarters > 2 > balance Sheet > cash
15108413
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
10487925
Quarters > 2 > balance Sheet > inventories
4098859
Quarters > 2 > balance Sheet > total Current Assets
31877151
Quarters > 2 > balance Sheet > property Plant Equipment
7476230
Quarters > 2 > balance Sheet > total Assets
69935878
Quarters > 2 > balance Sheet > payables
13927623
Quarters > 2 > balance Sheet > short Term Debt
371094
Quarters > 2 > balance Sheet > long Term Debt
5240733
Quarters > 2 > balance Sheet > total Liabilities
41595259
Quarters > 2 > balance Sheet > equity
28657020
Quarters > 2 > cash Flow > net Income
1248184
Quarters > 2 > cash Flow > depreciation
1316768
Quarters > 2 > cash Flow > change In Working Capital
1127833
Quarters > 2 > cash Flow > cash From Operations
3898517
Quarters > 2 > cash Flow > capital Expenditures
47630
Quarters > 2 > cash Flow > cash From Investing
-1228186
Quarters > 2 > cash Flow > cash From Financing
-5526102
Quarters > 2 > cash Flow > net Change In Cash
-2855771
Quarters > 2 > ratios > PE
0.08237762113114803
Quarters > 2 > ratios > PB
1.3312465846064945
Quarters > 2 > ratios > ROE
4.386597071153944
Quarters > 2 > ratios > ROA
1.7974579514108624
Quarters > 2 > ratios > FCF
3850887
Quarters > 2 > ratios > Piotroski FScore
4
Quarters > 2 > ratios > fcf Percent
0.32876879686811
Quarters > 2 > health Score
65
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
10435569
Quarters > 3 > income Statement > cost Of Revenue
1976473
Quarters > 3 > income Statement > gross Profit
8459096
Quarters > 3 > income Statement > operating Expenses
10301135
Quarters > 3 > income Statement > operating Income
-1842039
Quarters > 3 > income Statement > interest Expense
223261
Quarters > 3 > income Statement > pretax Income
-1958633
Quarters > 3 > income Statement > net Income
-1903814
Quarters > 3 > income Statement > eps
-0.13626676194819812
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
13971228
Quarters > 3 > income Statement > income Tax Expense
-56996
Quarters > 3 > income Statement > EBITDA
46207
Quarters > 3 > income Statement > operating Margin
-17.65154348555407
Quarters > 3 > income Statement > total Other Income Expense Net
-116594
Quarters > 3 > balance Sheet > cash
17964184
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
11701466
Quarters > 3 > balance Sheet > inventories
3999995
Quarters > 3 > balance Sheet > total Current Assets
36452158
Quarters > 3 > balance Sheet > property Plant Equipment
6454288
Quarters > 3 > balance Sheet > total Assets
75583410
Quarters > 3 > balance Sheet > payables
13914266
Quarters > 3 > balance Sheet > short Term Debt
5456508
Quarters > 3 > balance Sheet > long Term Debt
10176170
Quarters > 3 > balance Sheet > total Liabilities
53037433
Quarters > 3 > balance Sheet > equity
22853494
Quarters > 3 > cash Flow > net Income
-1901637
Quarters > 3 > cash Flow > depreciation
1781579
Quarters > 3 > cash Flow > change In Working Capital
2425532
Quarters > 3 > cash Flow > cash From Operations
1904618
Quarters > 3 > cash Flow > capital Expenditures
26809
Quarters > 3 > cash Flow > cash From Investing
-26809
Quarters > 3 > cash Flow > cash From Financing
-1378379
Quarters > 3 > cash Flow > net Change In Cash
499430
Quarters > 3 > ratios > PE
-0.13626676194819812
Quarters > 3 > ratios > PB
1.5283470440012368
Quarters > 3 > ratios > ROE
-8.33051611276595
Quarters > 3 > ratios > ROA
-2.518825228975512
Quarters > 3 > ratios > FCF
1877809
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
0.1799431348688318
Quarters > 3 > health Score
38
Valuation > metrics > PE
-0.12978275162726302
Valuation > metrics > PB
1.4312813540228824
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-7.430225299115378
Profitability > metrics > ROA
-6.482297202005862
Profitability > metrics > Net Margin
-0.2340423633218135
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
1.5351485502177769
Risk > metrics > Interest Coverage
-17.915022014785915
Risk > final Score
-42
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.103384150363968
Liquidity > metrics > Quick Ratio
1.8972063396071166
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
100
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
37
Prev Profitabilities > 2
0
Prev Risks > 0
3
Prev Risks > 1
62
Prev Risks > 2
-15
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
97
Updated At
2025-12-13T15:22:46.088Z
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an injection for the prevention of nausea and vomiting for patients receiving chemotherapy treatment; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of the cardiomyopathy associate with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, and aspirin-exacerbated respiratory disease; and is in Phase II clinical trial for the treatment of systemic sclerosis and idiopathic pulmonary fibrosis. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Stock Price
$ 0.00
0% increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AHighs Report: Will CPIX stock maintain growth story - Trade Analysis Report & High Accuracy Trade Alerts moha.gov.vn
Read more →Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Shares Fly 26% But Investors Aren't Buying For Growth simplywall.st
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$8.5
Analyst Picks
Strong Buy
1
Buy
0
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 30.04% of the total shares of Cumberland Pharmaceuticals Inc
1.
Millennium Management LLC(5.187%)
since
2025/06/30
2.
Ikarian Capital, LLC(3.9835%)
since
2025/06/30
3.
Renaissance Technologies Corp(3.3086%)
since
2025/06/30
4.
Vanguard Group Inc(2.7526%)
since
2025/06/30
5.
Vanguard Total Stock Mkt Idx Inv(1.837%)
since
2025/07/31
6.
Dimensional Fund Advisors, Inc.(1.6904%)
since
2025/06/30
7.
J. Goldman & Co LP(1.4753%)
since
2025/06/30
8.
Bridgeway Capital Management, LLC(1.2591%)
since
2025/06/30
9.
BOOTHBAY FUND MANAGEMENT, LLC(1.2047%)
since
2025/06/30
10.
Bridgeway Ultra-Small Company(0.9176%)
since
2025/06/30
11.
Geode Capital Management, LLC(0.67%)
since
2025/06/30
12.
Vanguard Institutional Extnd Mkt Idx Tr(0.5812%)
since
2025/07/31
13.
Citadel Advisors Llc(0.4974%)
since
2025/06/30
14.
Bank of New York Mellon Corp(0.4847%)
since
2025/06/30
15.
DFA US Targeted Value I(0.4385%)
since
2025/07/31
16.
BlackRock Inc(0.342%)
since
2025/06/30
17.
Bridgeway Ultra-Small Company Market(0.3335%)
since
2025/06/30
18.
DFA US Micro Cap I(0.3193%)
since
2025/07/31
19.
Fidelity Extended Market Index(0.2953%)
since
2025/07/31
20.
Dimensional US Targeted Value ETF(0.2626%)
since
2025/08/29
21.
State Street Corp(0.2253%)
since
2025/06/30
22.
Heron Bay Capital Management(0.2223%)
since
2025/06/30
23.
Two Sigma Investments LLC(0.2157%)
since
2025/06/30
24.
Northern Trust Corp(0.131%)
since
2025/06/30
25.
Cresset Asset Management, LLC(0.1302%)
since
2025/06/30
26.
Dimensional US Small Cap ETF(0.125%)
since
2025/08/29
27.
Fidelity Total Market Index(0.1203%)
since
2025/07/31
28.
iShares Micro-Cap ETF(0.1129%)
since
2025/08/31
29.
Dimensional US Marketwide Value ETF(0.1015%)
since
2025/08/29
30.
Dimensional Global Trgtd Value USD Acc(0.0972%)
since
2025/07/31
31.
SIMPLEX TRADING, LLC(0.095%)
since
2025/06/30
32.
Morgan Stanley - Brokerage Accounts(0.0829%)
since
2025/06/30
33.
Susquehanna International Group, LLP(0.0771%)
since
2025/06/30
34.
Fidelity Series Total Market Index(0.0763%)
since
2025/07/31
35.
Fidelity Nasdaq Composite Index(0.0757%)
since
2025/07/31
36.
Spartan Extended Market Index Pool F(0.0727%)
since
2025/07/31
37.
NT Ext Equity Mkt Idx Fd - NL(0.0684%)
since
2025/06/30
38.
Northern Trust Extended Eq Market Idx(0.0599%)
since
2025/06/30
39.
NT Ext Equity Mkt Idx Fd - L(0.0599%)
since
2025/06/30
40.
NT Ext Equity Mkt Idx Fd - DC - NL - T2(0.0531%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.